Format

Send to

Choose Destination
Clin Cancer Res. 2018 Jan 15;24(2):253-255. doi: 10.1158/1078-0432.CCR-17-2823. Epub 2017 Oct 30.

Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?

Author information

1
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. j.f.marshall@qmul.ac.uk.

Abstract

Cadherin-17 (CDH17) has been implicated as protumorigenic for many years, but mechanisms have been unclear. A Spanish team has generated antibodies to an RGD motif in CDH17 that inhibits integrin α2β1 binding to CDH17 and thereby inhibits integrin activation, tumorigenesis, and metastasis. These reagents may have therapeutic potential. Clin Cancer Res; 24(2); 253-5. ©2017 AACRSee related article by Bartolomé et al., p. 433.

PMID:
29084915
DOI:
10.1158/1078-0432.CCR-17-2823
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center